AIM Immunotech
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • CEO Corner
    • Partnering
  • Science
    • Pipeline
    • Ampligen®
    • Immuno-Oncology
    • Immune Disorders
    • Viral Diseases
    • Orphan Drug Designation
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Company Info
      • Profile
      • Management Team
    • Presentations
    • Events
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
      • Governance Documents
      • Board of Directors
      • Committee Composition
    • Stockholder Meeting
    • Email Alerts
    • Investor Contact
  • Contact Us
Select Page

Hemispherx Biopharma CFO Adam Pascale Announces Retirement

by Barry101 | Jun 28, 2019 | Press Release

OCALA, Fla., June 28, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after nearly a quarter century with the company.Pascale joined Hemispherx in 1995 as an...

Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program

by Barry101 | Jun 17, 2019 | Press Release

OCALA, Fla., June 17, 2019 — Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor microenvironments and increase the effectiveness of...

Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin

by Barry101 | Jun 12, 2019 | Press Release

OCALA, Fla., June 12, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) (See:...

Hemispherx Biopharma Stockholders Approve Reverse Stock Split

by Barry101 | May 31, 2019 | Press Release

OCALA, Fla., May 31, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, today announced that its stockholders...

Hemispherx Reports 2019 First Quarter Financial Results

by Barry101 | May 16, 2019 | Press Release

OCALA Fla., May 16, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces financial results for the...

Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center

by Barry101 | May 13, 2019 | Press Release

OCALA, Fla., May 13, 2019 — Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced progress toward the opening...
« Older Entries
Next Entries »

Recent Posts

  • AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
  • AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
  • AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
  • AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
  • AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference

Recent Comments

No comments to show.
Get Notified

Sign up to have the latest news and information delivered directly to your inbox!

Sign Up Now

Contact Us

AIM ImmunoTech
2117 SW Highway 484
Ocala, FL 34473
Phone: 352-448-7797
Fax: 352-480-4620
Email: info@AIMimmuno.com

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AIM@jtcir.com

©2025 AIM ImmunoTech     All Rights Reserved
  • Privacy Policy
  • Terms of Use
  • Follow
  • Follow
  • Follow